Sepracor enters Lunesta marketing pact with GSK for Europe, Japan

Share this article:

In hopes to boost its profits amid cheaper competition, Sepracor has entered into a marketing deal with GlaxoSmithKline to market its sleep drug Lunesta outside North America.

Under terms of the deal, Sepracor will receive an initial payment of $20 million, plus additional milestone payments, reaching up to $155 million.

Lunesta's US sales have slowed since this spring when cheaper generic copies of Sanofi-Aventis' rival sleeping pill Ambien were made available.

Lunesta was approved in 2005 and had US sales of approximately $567 million last year.

Lunesta will be marketed under the brand name Lunivia in Europe and Japan. The drug is expected to be approved in Europe, where the insomnia market is estimated to be at $500 million, by the second half of 2008, Sepracor and GSK said.

Lunivia has the potential for authorization in as many as 27 EU member countries, the drugmakers said.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.